kabutan

MediciNova,Inc.(4875) Summary

4875
TSE Standard
MediciNova,Inc.
236
JPY
+7
(+3.06%)
Dec 5, 1:23 pm JST
1.52
USD
Dec 4, 11:23 pm EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
230 JPY 1.48 USD
Previous Close Dec 4
229 JPY 1.47 USD
High Dec 5, 10:32 am
242 JPY 1.56 USD
Low Dec 5, 9:00 am
230 JPY 1.48 USD
Volume
145,800
Trading Value
0.04B JPY 0.22M USD
VWAP
237.29 JPY 1.53 USD
Minimum Trading Value
23,600 JPY 152 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
313
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
196
1-Year High Nov 5, 2025
3,850
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 50,200
Nov 21, 2025 0 51,700
Nov 14, 2025 0 67,600
Nov 7, 2025 0 60,100
Oct 31, 2025 0 59,500
Company Profile
MediciNova, Inc. is a US-based pharmaceutical development venture focusing on treatments for conditions such as acute asthma attacks.
Sector
Pharmaceuticals
MediciNova, Inc. is a pharmaceutical development company headquartered in the United States, specializing in the development of novel therapeutics for serious diseases. Its lead development product, MN-166 (ibudilast), is being developed for indications including ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence, alcohol use disorder, and Long-COVID. MN-001 (tipelukast) is being developed for non-alcoholic fatty liver disease and idiopathic pulmonary fibrosis. Additionally, a treatment for phenylketonuria is included in the development pipeline. The company has received Fast Track and Orphan Drug designations from the US FDA for several of its development products, indicating a promising development pipeline.